The International Staging System (ISS) and Revised ISS (R-ISS) are the two most up-to-date prognostic staging systems for multiple myeloma. See details. In 2005, a new staging system was developed by the IMF's research division, the International Myeloma Working Group (IMWG).

The Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely obtained lab values.

Prognostication tool for myeloma patients based on the genetics and other routinely used lab values in conjunction with the original ISS Staging System. Use only in patients recently diagnosed with multiple myeloma. Do not use in patients with relapsed myeloma, smoldering myeloma or MGUS.

2022年5月23日 · Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model.

The Revised International Staging System. Multiple myeloma is staged using the Revised International Staging System (R-ISS), which is based on 4 factors: The amount of beta-2-microglobulin (B2M) in the blood; The amount of albumin in the blood; The amount of lactate dehydrogenase (LDH) in the blood

2005年5月20日 · This new International Staging System (ISS) was validated in the remaining patients and consists of the following stages: stage I, Sbeta2M less than 3.5 mg/L plus serum albumin > or = 3.5 g/dL (median survival, 62 months); stage II, neither stage I nor III (median survival, 44 months); and stage III, Sbeta2M > or = 5.5 mg/L (median survival, 29 ...

2015年8月3日 · A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization after CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prognostic value in newly diagnosed MM (NDMM).

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

The International Staging System (ISS) is the standard prognostic tool for multiple myeloma. It uses two simple blood tests - serum β2-microglobulin and serum albumin - to classify patients into three stages with different survival outcomes.

ISS分期系统主要取决于一些简单的实验室指标，与Durie-Salmon分期相比更为简单客观，并能提示预后。 1. 王吉耀主编. 《内科学》（八年制） [M]. 人民卫生出版社.2005年. 2. Greipp PR et al.International Staging System for Multiple Myeloma.JCO 2005;23:3412-3420.